As the TKI-class is also used as one of the main therapeutic options in ccRCC, a similar mechanism in ccRCC could indicate RCN1 suppression to be a promising addition to TKI-based therapies. The gene discussed is RCN1; the disease is nonpapillary renal cell carcinoma.